PathAI
AI-powered pathology solutions designed to improve diagnostic accuracy and drug development.
What they do
The company provides machine learning tools to assist pathologists in diagnosing diseases like cancer. It partners with biopharmaceutical companies to evaluate drug efficacy in clinical trials and sells diagnostics tools to reference laboratories.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Digital pathology software
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Boston, USA
- Region
- North America
- Founded
- 2016
- Total funding
- $255M raised
Notable investors: General Catalyst, Tiger Global Management, D1 Capital Partners, General Atlantic.